Immune booster drug tested on rare cancers
NCT ID NCT07089992
First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 3 times
Summary
This study is testing a drug called pembrolizumab in people with ultra-rare sarcomas, a group of very uncommon cancers. The drug works by releasing the immune system's brakes so it can attack cancer cells. Researchers want to see if it can shrink tumors or stop them from growing, and if side effects are manageable. About 32 people with specific sarcoma types will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (a drug that helps the immune system attack cancer cells)
- What this could lead to
- If it works, this could point toward a new treatment option for people with ultra-rare sarcomas that are hard to treat.
- What could go wrong
- This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. The drug may not work for all sarcoma types and can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIC-REARRANGED SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities)
RECRUITINGCommack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (All Protocol Activities)
RECRUITINGUniondale, New York, 11553, United States
-
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering at Westchester (Limited Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle childhood sarcoma?
- Can a Patient's own immune cells be engineered to fight a rare sarcoma?
- Can a Patient's own immune cells fight advanced sarcoma?
- Could a massive tissue bank unlock sarcoma's secrets?
- Can a new drug shrink Hard-to-Treat childhood cancers?
- Can a new protein drug shield kids with cancer from dangerous infections?